Poxel (FRA:7PO) Total Operating Expense: €5.74 Mil (TTM As of Jun. 2025)


FRA:7PO Poxel SA FRA:7PO
37 GF Score
Price €0.20
GF Value €1.30
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Poxel Total Operating Expense?

Poxel FRA:7PO -1.29% 37 Total Operating Expense is €5.74 Mil as of Jun. 2025. GuruFocus rates FRA:7PO with a GF Score™ of 37/100 and a GF Value™ of €1.30 (Possible Value Trap). The stock has 6 warning signs investors should review.

Poxel's Total Operating Expense for the six months ended in Jun. 2025 was €2.27 Mil. Poxel's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2025 was €5.74 Mil.

Poxel Total Operating Expense Related Terms

Poxel Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Poxel's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poxel Total Operating Expense Chart

Poxel Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.63 35.80 21.89 28.76 7.19

Poxel Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.28 5.49 3.73 3.47 2.27
FRA:7PO
37GF Score
Poxel SA FRA:7PO
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Poxel Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €5.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €5.74 Mil mean?
Poxel (FRA:7PO) has a Total Operating Expense of €5.74 Mil as of Jun. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Poxel and its competitors.
Is Poxel's Total Operating Expense too high?
Poxel's current Total Operating Expense is €5.74 Mil. Overall, Poxel has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Poxel's Total Operating Expense compare to VRTX and REGN?
Poxel's Total Operating Expense of €5.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Poxel and its competitors. Poxel's current Total Operating Expense is €5.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poxel stock overvalued right now?
Based on GuruFocus' analysis, Poxel (FRA:7PO) is currently considered Possible Value Trap. The stock's GF Value™ is €1.30, compared to a current price of €0.20 — trading 84.7% below its estimated fair value. The current Total Operating Expense is €5.74 Mil. Poxel's overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Poxel (FRA:7PO), the current Total Operating Expense is €5.74 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Poxel (FRA:7PO) Overvalued in 2026?

Based on GuruFocus' analysis, Poxel stock appears to be undervalued. The current stock price of €0.20 is trading 84.7% below its estimated GF Value™ of €1.30. GuruFocus considers Poxel to be Possible Value Trap.

Key valuation signals for FRA:7PO:

  • Total Operating Expense: €5.74 Mil
  • GF Value™: €1.30 vs. price of €0.20 (84.7% below fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the FRA:7PO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Poxel Business Description

Other Exchanges 0RA2:UKPOXEL:France
Address 259/261 Avenue Jean Jaures, Immeuble le Sunway, Lyon, FRA, 69007
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
37GF Score

Get the complete analysis for FRA:7PO

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€1.30
GF Value